Amylyx Pharmaceuticals, Inc. (AMLX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

-150M 0 150M 300M 450M Q2 '23: 191.9M Q3 '23: 294.2M Q4 '23: 380.8M Q1 '24: 398M Q2 '24: 298.8M Q3 '24: 196.5M Q4 '24: 87.4M Q1 '25: -1.3M Q2 '25: -249K Q3 '25: -665K Q4 '25: 0 Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25

Gross Profit TTM

-150M 0 150M 300M 450M Q2 '23: 178M Q3 '23: 275.3M Q4 '23: 355.3M Q1 '24: 371.9M Q2 '24: 278.2M Q3 '24: 181.2M Q4 '24: 81.4M Q1 '25: -1.3M Q2 '25: -249K Q3 '25: -665K Q4 '25: 0 Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income TTM

-450M -300M -150M 0 150M 300M 450M Q4 '21: -82.7M Q1 '22: -117.6M Q2 '22: -153.3M Q3 '22: -185.1M Q4 '22: -201.3M Q1 '23: -155.6M Q2 '23: -81.1M Q3 '23: -7.7M Q4 '23: 38.8M Q1 '24: -81.3M Q2 '24: -177.8M Q3 '24: -272.1M Q4 '24: -314.7M Q1 '25: -230.4M Q2 '25: -197M Q3 '25: -157.3M Q4 '25: -153.3M Q1 '26: -159.3M Q2 '26: -162.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-450M -300M -150M 0 150M 300M 450M Q4 '21: -87.9M Q1 '22: -121.3M Q2 '22: -153.4M Q3 '22: -184M Q4 '22: -198.4M Q1 '23: -149M Q2 '23: -72.8M Q3 '23: 1.8M Q4 '23: 49.3M Q1 '24: -71.1M Q2 '24: -165.9M Q3 '24: -259.5M Q4 '24: -301.7M Q1 '25: -218.9M Q2 '25: -187.6M Q3 '25: -149.3M Q4 '25: -144.7M Q1 '26: -150.1M Q2 '26: -152.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

0 9M 18M 27M Q2 '23: 13.9M Q3 '23: 18.9M Q4 '23: 25.4M Q1 '24: 26.1M Q2 '24: 20.5M Q3 '24: 15.3M Q4 '24: 6M Q1 '25: 8K Q2 '25: 0 Q3 '25: 0 Q4 '25: 0 Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25

Operating Cash Flow TTM

-240M -160M -80M 0 80M 160M 240M Q4 '21: -74.8M Q1 '22: -102.8M Q2 '22: -136.2M Q3 '22: -158.4M Q4 '22: -179.9M Q1 '23: -144.3M Q2 '23: -89.2M Q3 '23: -51.3M Q4 '23: 11.9M Q1 '24: 16.5M Q2 '24: -58.7M Q3 '24: -95.1M Q4 '24: -167.6M Q1 '25: -207M Q2 '25: -165.7M Q3 '25: -154.4M Q4 '25: -123.3M Q1 '26: -120.4M Q2 '26: -126.6M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-240M -160M -80M 0 80M 160M 240M Q4 '21: -75.2M Q1 '22: -103.5M Q2 '22: -138M Q3 '22: -160.5M Q4 '22: -182.4M Q1 '23: -146.7M Q2 '23: -90.8M Q3 '23: -52.8M Q4 '23: 10.7M Q1 '24: 15.4M Q2 '24: -59.6M Q3 '24: -95.6M Q4 '24: -167.8M Q1 '25: -207.1M Q2 '25: -165.7M Q3 '25: -154.5M Q4 '25: -123.5M Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 40M 80M 120M Q2 '21: 6.4M Q3 '21: 6.8M Q1 '22: 51.6M Q2 '22: 58.3M Q3 '22: 58.5M Q1 '23: 70.9M Q2 '23: 70.1M Q3 '23: 69.7M Q1 '24: 67.9M Q2 '24: 68M Q3 '24: 68.1M Q1 '25: 85.7M Q2 '25: 89.1M Q3 '25: 93.3M Q1 '26: 110.6M Q2 '26: 111.2M Q3 '21 Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-15.00 -10.00 -5.00 0.00 5.00 10.00 15.00 Q4 '21: -13.31 Q1 '22: -11.91 Q2 '22: -9.43 Q3 '22: -6.93 Q4 '22: -3.40 Q1 '23: -2.45 Q2 '23: -1.21 Q3 '23: 0.01 Q4 '23: 0.70 Q1 '24: -1.07 Q2 '24: -2.45 Q3 '24: -3.82 Q4 '24: -4.43 Q1 '25: -3.10 Q2 '25: -2.49 Q3 '25: -1.79 Q4 '25: -1.53 Q1 '26: -1.48 Q2 '26: -1.41 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.